EU-Japan Webinar Series on COVID-19
Research and Innovation
Professor Peter PiotLondon School of Hygiene & Tropical Medicine
17 September 2020

240+ COVID-19 vaccine candidates in the pipeline

Source: LSHTM COVID-19 Vaccine Tracker

Massive investments-Big investments from companies developing vaccines (e.g. AstraZeneca, GSK, J&J, Merck, Pfizer, and Sanofi)
The European Commission, Japan, and partners raised €15.9 billion as part of the Coronavirus Global Response
US Operation Warp Speed programme has announced more than US$10 billion to advance vaccine R&D
Coalition for Epidemic Preparedness Innovations portfolio includes 8 clinical candidates and is being advanced
under COVAX
Sources: CEPI (4 Sept 2020); EC 2020 (15/09/2020)

Vaccine Pipeline: Phases I-III
Phase III••••

Moderna/NIAID
CanSino Biological Inc/Beijing Institute of Biotechnology
Gamaleya Research Institute
Janssen Pharmaceutical Companies/Beth Israel Deaconess
Medical Center••••

University of Oxford/AstraZeneca
Beijing Institute of Biological Products/SinopharmSinovac/Instituto Butantan
Wuhan Institute of Biological Products/SinopharmPhase II/III•

BioNTech/Fosun Pharma/Pfizer

Phase II•
•CureVacAnhui Zhifei Longcom Biopharmaceutical/Chinese Academy ofSciences•

Novavax

Phase I/II••••••

Arcturus/Duke-NUS
Genexine Consortium
Inovio Pharmaceuticals/International Vaccine Institute
Osaka University/AnGes/Takara Bio
Zydus Cadila Healthcare Limited (DNA)
Bharat Biotech/ICMR/National Institute of Virology

•••
•
•
•

Institute of Medical Biology/Chinese Academy of Medical Sciences
Research Institute for Biological Safety Problems (inactivated)
FBRI SRC VB VECTOR/Rospotrebnadzor, Koltsovo/(peptide)
Instituto Finlay de Vacunas
Kentucky Bioprocessing Inc
Sanofi Pasteur/GSKPhase I•••••••••Imperial College London
PLA Academy of Military Sciences/Walvax Biotech
Symvivo
ReiThera/Leukocare/Univercells
Beijing Wantai Biological Pharmacy/Xiamen University
Institut Pasteur/Themis/University of Pittsburg/Merck
Merck
Adimmune Corporation
Clover Biopharmaceuticals Inc/GSK/Dynavax

••••
•••
•
•

Covaxx/University of Nebraska Medical Center
Medigen Vaccine Biologics Corporation/NAID/Dynavax
University of Queensland/CSL/Seqirus
Vaxine Pty/Medytox
West China Hospital/Sichuan University
Medicago Inc/GSK/Dynavax
Aivita Biomedical Inc
Shenzhen Geno-Immune Medical Institute/(modified APC)
Shenzhen Geno-Immune Medical Institute/(modified DC)

COVID-19 vaccine initiatives in Europe and Africa

Will Vaccines end the pandemic?
Challenges ahead for a safe and effective COVID-19 vaccine:
1. Will it work? For how long?
2. Will it be safe?
3. Will there be enough?
4. Who gets it first?
5. Will people accept it?
There are no silver bullets!

Source: Figueiredo et al 2020

Societies living with COVID-19••
•
•
•
•
•
•
•
•
•••
•

Future waves
Series of outbreaks - No time to lose!
Safe spaces for vulnerable communities
Long-term care for survivors
Social sciences and epidemiology
Research and innovation
Wider health impacts of COVID-19 response
Mental health and wellbeing
Healthy longevity and social careAcute and long-term social and economic costs
Rethinking how we work
Urban planning
Access to internet
Are we ready for the next pandemic?

No country is safe,
unless every country
is safe